CAAP Company: iTP Biomedica Launches BladderPredict, A State-Of-The-Art Diagnostic To Manage Early Stage Bladder Cancer

July 19, 2016 TORONTO – iTP Biomedica Corp., a developer of proprietary whole transcriptome-based cancer diagnostics, today announced the launch of BladderPredict, a groundbreaking next-generation sequencing-based test that will for the first time assist uro-pathologists in assigning disease grade in early stage bladder cancer, and urologists and uro-oncologists in managing the disease.  The test will be provided in collaboration with iTP’s partner, Mount Sinai Services of Toronto, a global provider of customized clinical laboratory and research services.

For the full press release, click here